Tag Archives: Martin Birkhofer

Licensing or Acquisition? Big Pharma Shares How They (and YOU) Decide

When I was at the Biocom Global Life Science Partnering Conference last week, one of the more interesting debates I heard was about whether it’s better to in-license an asset or acquire the whole company. While every case is different…

Share